NEW YORK – Breast cancer diagnostic firm PreludeDx announced on Tuesday that it has closed a $20 million funding round.
The round was led by Evidity Health Capital and joined by existing and new investors, the company said in a statement. Evidity Managing Director Alejandro Sanchez will join the firm's board of directors, it added.
The money will be used to further advance the commercial market expansion of PreludeDx's DCISionRT risk assessment test for breast cancer and continue development of the company's precision radiogenomics platform for early-stage cancers, the Laguna Hills, California-based firm said.
DCISionRT is a molecular assay for patients with ductal carcinoma in situ that predicts radiation therapy benefit. It measures protein expression from seven biomarkers, as well as clinicopathologic factors, to provide a personalized recurrence risk score after breast conserving surgery alone and with the addition of radiation therapy.